Oral fedratinib therapy (200 mg a day, owing to JAK-2 pathogenic gene variants) was continued, because the association between fedratinib and uveitis was initially nuclear and fedratinib was effective for splenomegaly. The gene discussed is JAK2; the disease is Splenomegaly.